Summit Therapeutics Inc. (SMMT)财务
NASDAQ · Healthcare · Biotechnology · 员工265人 · CEO Robert W. Duggan
- 股价
- $16.03 -1.05%
- 市值
- $128亿
- 企业价值
- $124亿
- 最近财报
- Q2 '26 2026-07-23提交
- 下次财报
- 2026-11-02 EPS预期 -$0.28
营收(TTM)–– 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)–– 对比去年同期营业利润 –
净利润(TTM)–– 对比去年同期税后,含营业外收益
自由现金流(TTM)–– 对比去年同期资本支出 –
稀释EPS(TTM)–– 对比去年同期最近4个季度之和
净现金$6.7亿+212.5% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $128亿 EV $124亿
- 营收
- – 过去12个月
- 营收增速
- – FY2026年一致预期
- 净利润率
- – 净利润 / 营收,TTM
- P/E
- -14.3× 预期 -13.8×(FY2026)
- P/S
- 0.0× 股价 / 营收,TTM
- EV / EBITDA
- -14.5× TTM
- 自由现金流
- – 过去12个月
- 净利润
- – 过去12个月
- 营收预期
- $366万 FY2026年一致预期
- 盈利
- 2026-11-02 营收预期 $7.21万
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-07-23):营收无,EPS 低于预期2.0%营收–,预期$11.4万(–);EPS -$0.28,预期-$0.27(-2.0%)。
- 稀释股数一年内增加4.8%Q2 '26稀释股数7.78亿,一年前为7.43亿。
- 净现金 $6.7亿现金 + 短期投资 $6.91亿,含租赁债务 $2040万;一年前净现金 $2.14亿。
上一季度:Q2 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q2 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $0 | $0 | – |
| 营业利润 | -$2.2亿 | -$4.14亿 | +46.8% |
| 净利润 | -$2.16亿 | -$4.12亿 | +47.7% |
| 稀释EPS | -$0.28 | -$0.56 | +50.0% |
| 经营现金流 | -$1.68亿 | -$4900万 | -242.6% |
| 资本支出 | $96.8万 | $0 | – |
| 自由现金流 | -$1.69亿 | -$4900万 | -244.6% |
| R&D | $1.58亿 | $1.52亿 | +4.1% |
| 股权激励费用 | $8630万 | $3.51亿 | -75.4% |
实际 vs 一致预期
2026-07-23| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| EPS(一致预期口径) | -$0.28 | -$0.27 | -2.0% |
来自2026-07-23发布的Q2 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q4 '22 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| License and Service | $397万 | +1,482.9% | 100.0% | $468万 | +158.6% |
按地区划分的营收
占总额比例| 分部 | Q4 '22 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Latin America | $22万 | -83.2% | 100.0% | $95.6万 | -45.2% |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 自由现金流
- –
- 股东回报 / FCF
- –
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -14.3× | – | – |
| EV / EBITDA | -14.5× | – | – |
| EV / 营收 | 0.0× | 892.7× 5年中的2年 | 147.2× – 1,638.1× |
| 股价 / FCF | -31.4× | – | – |
| 股价 / 净资产 | 19.8× | 21.2× | 4.0× – 41.0× |
| FCF收益率 | -3.2% | -6.5% | -21.8% – -0.9% |
| 投入资本回报率 | -134.1% | -141.5% | -326.0% – -11.3% |
| 净资产收益率 | -204.3% | -246.3% | -784.6% – -56.9% |
分析师
一致目标价 $31.00 (+93.4%)
区间 $20.00 – $41.00 · 评级 Buy
强烈买入0
买入15
持有8
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $366万 | – | -$1.16 | +19.4% | -13.8× | 9 |
| FY2027 | $5950万 | +1,528.4% | -$1.13 | +2.4% | -14.2× | 8 |
| FY2028 | $5.81亿 | +876.5% | -$0.69 | +39.0% | -23.2× | 7 |
| FY2029 | $17亿 | +193.2% | $0.09 | +112.7% | 182.1× | 2 |
| FY2030 | $38.3亿 | +124.9% | $1.57 | +1,681.7% | 10.2× | 4 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Summit Therapeutics Inc.在近期10-Q / 10-K文件中标记的全部168项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $2290万 | $2300万 | -0.4% | $2030万 | $464万 | +337.7% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $297万 | $102万 | +190.2% | $701万 | $258万 | +172.0% |
| Accrued Liabilities, Current | $6510万 | $2610万 | +148.8% | $3210万 | $1960万 | +64.2% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$267万 | -$275万 | +3.2% | -$254万 | -$229万 | -11.2% |
| Additional Paid in Capital | $33.2亿 | $21亿 | +58.4% | $29.5亿 | $16亿 | +84.4% |
| Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $346万 | – | – | $61.9万2023-12-31 | $11.1万 | +457.7% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 21.3万 | 4350万 | -99.5% | 1.16亿 | 7360万 | +57.1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $6870万 | $4.79亿 | -85.6% | $7.32亿 | $5100万 | +1,336.7% |
| Assets | $7.52亿 | $3.24亿 | +132.1% | $7.51亿 | $4.36亿 | +72.5% |
| Assets, Current | $7.21亿 | $3.09亿 | +133.0% | $7.2亿 | $4.24亿 | +70.0% |
| Capital Expenditures Incurred but Not yet Paid | -$74.6万 | $7.2万 | -1,136.1% | $29.1万 | $0 | – |
| Cash | $8490万 | $427万 | +1,890.6% | $1640万 | $1630万 | +0.6% |
| Cash and Cash Equivalents, at Carrying Value | $4.19亿 | $2.98亿 | +40.8% | $2.25亿 | $1.05亿 | +114.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $4.2亿 | $2.98亿 | +40.7% | $2.26亿 | $1.05亿 | +114.5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $3.13亿 | $8630万 | +262.3% | $1.2亿 | $3380万 | +256.6% |
| Class of Warrant or Right, Outstanding | 0 | 0 | – | 0 | 463万 | -100.0% |
| Common Stock, Par or Stated Value Per Share | $0.01 | $0.01 | 0.0% | $0.01 | $0.01 | 0.0% |
| Common Stock, Shares Authorized | 10亿 | 10亿 | 0.0% | 10亿 | 10亿 | 0.0% |
| Common Stock, Shares, Issued | 7.93亿 | 7.43亿 | +6.8% | 7.75亿 | 7.38亿 | +5.1% |
| Common Stock, Shares, Outstanding | 7.93亿 | 7.43亿 | +6.8% | 7.75亿 | 7.38亿 | +5.1% |
| Common Stock, Value, Issued | $793万 | $743万 | +6.8% | $775万 | $738万 | +5.1% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$2.16亿 | -$5.66亿 | +61.9% | -$10.8亿 | -$2.21亿 | -388.3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current Foreign Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current State and Local Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | $0 | – | $17.2万 | $10万 | +72.0% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $7.1万 | $0 | – | $0 | $0 | – |
| DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest | $0 | $0 | – | $0 | $0 | – |
| DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss | $6.06亿 | $2.94亿 | +106.3% | $6.97亿 | $3.96亿 | +76.0% |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterest | $6.06亿 | $2.94亿 | +106.3% | $6.97亿 | $3.96亿 | +76.0% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Tax Assets, Gross | $1.34亿2025-12-31 | $9590万 | +39.3% | $1.34亿 | $9590万 | +39.3% |
| Deferred Tax Assets, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Operating Loss Carryforwards | $7360万2025-12-31 | $5940万 | +23.8% | $7360万 | $5940万 | +23.8% |
| Deferred Tax Assets, Other | $71.1万2025-12-31 | $47.5万 | +49.7% | $71.1万 | $47.5万 | +49.7% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $1610万2025-12-31 | $787万 | +104.5% | $1610万 | $787万 | +104.5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $3220万2025-12-31 | $1400万 | +129.7% | $3220万 | $1400万 | +129.7% |
| Deferred Tax Assets, Valuation Allowance | $1.33亿2025-12-31 | $9560万 | +39.3% | $1.33亿 | $9560万 | +39.3% |
| Deferred Tax Liabilities, Gross | $41.7万2025-12-31 | $33.7万 | +23.7% | $41.7万 | $33.7万 | +23.7% |
| Deferred Tax Liabilities, Other | $41.7万2025-12-31 | $33.7万 | +23.7% | $41.7万 | $33.7万 | +23.7% |
| Depreciation | $4.6万 | $3.7万 | +24.3% | $14.6万 | $8.9万 | +64.0% |
| Earnings Per Share, Basic | -$0.28 | -$0.76 | +63.2% | -$1.44 | -$0.31 | -364.5% |
| Earnings Per Share, Diluted | -$0.28 | -$0.76 | +63.2% | -$1.44 | -$0.31 | -364.5% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $1000 | $6.1万 | -98.4% | $10.2万 | -$1.8万 | +666.7% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$2.27亿 | -$4650万 | -387.8% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 21.0% | 21.0% | 0.0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $2920万 | $857万 | +240.9% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -2.7% | -4.0% | +32.5% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | – | – | – | $1.34亿 | -$13万 | +103,202.3% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | – | – | – | -12.4% | 0.1% | -12,500.0% |
| Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | – | – | – | $29.9万 | $7.7万 | +288.3% |
| Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | – | – | – | 0.0% | 0.0% | – |
| Effective Income Tax Rate Reconciliation, Percent | – | – | – | 0.0% | 0.0% | – |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | – | – | – | $0 | -$1.7万 | +100.0% |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | – | – | – | 0.0% | 0.0% | – |
| Effective Income Tax Rate Reconciliation, Tax Contingency, Amount | – | – | – | $136万 | $95.6万 | +41.9% |
| Effective Income Tax Rate Reconciliation, Tax Contingency, Percent | – | – | – | -0.1% | -0.4% | +75.0% |
| Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | – | – | – | $683万 | $478万 | +42.8% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-02